The Role of Epigenetic Modifications in Cardiometabolic Diseases

Kim V.E. Braun, Eliana Portilla, Jana Nano, Jenna Troup, Trudy Voortman, Oscar H. Franco, Taulant Muka

Research output: Chapter/Conference proceedingChapterAcademic

2 Citations (Scopus)


The risk of cardiometabolic disease such as type II diabetes and cardiovascular disease (CVD) increases with age. Both of these diseases are important determinants of overall health and longevity. Although environmental and genetic studies have improved our understanding of the etiology and pathophysiologic mechanisms associated with diabetes and CVD, the etiology for the majority of these traits remains poorly understood. Alterations in the epigenetic mechanisms, including DNA methylation and histone modification, have been recently implicated in the onset and progression of cardiometabolic outcomes and may account for the missing heritability determinants of these diseases. Despite a growing body of literature addressing the role of the environment in gene expression affecting cardiometabolic risk, little is known about the epigenetic pathways involved in the pathophysiology of diabetes and CVD. In this chapter we describe the current knowledge about epigenetic control mechanisms in the development of cardiometabolic diseases.

Original languageEnglish
Title of host publicationEpigenetics of Aging and Longevity
Subtitle of host publicationTranslational Epigenetics vol 4
PublisherElsevier Inc.
Number of pages18
ISBN (Electronic)9780128110607
ISBN (Print)9780128110836
Publication statusPublished - 1 Jan 2018

Bibliographical note

Publisher Copyright:
© 2018 Elsevier Inc. All rights reserved.


Dive into the research topics of 'The Role of Epigenetic Modifications in Cardiometabolic Diseases'. Together they form a unique fingerprint.

Cite this